FDA Rejects Generic Tablets Larger Than Brand Citing Safety And Efficacy Concerns

FDA denies ANDAs for one product because the generic tablet size is larger than the brand; the agency plans to release a draft guidance on generic equivalency to the reference listed drug in size, taste and smell.